Purified interleukin 2
US4925919A · kind A · utility
21Cited by
23References
22Claims
0Family size
Inventors
Key dates
| Filing date | Jun 10, 1988 |
| Grant date | May 15, 1990 |
| Priority date | — |
| Expiry date | Jun 10, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH.sub.4).sub.2 SO.sub.4 -precipitation, ion-exchange chromatogr This invention was made with support in part under Grants CA 08748, CA 22507, CA 25608, CA 20194, CA 21525, CA31525, P01-CA-20194, AI 18 321-01, CA 23766 and CA 33050 awarded by the National Cancer Institute, National Institute of Health, DHEW. The government has certain rights in this invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.